Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.39 |
| ▸ | HRH1 | P35367 | 7/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12881013 | 1.00 | CYP2D6 (0.50) | CYP2D6CYP2C19HRH3HRH1GNAI3 | |
| SCHEMBL23682741 | 0.94 | CYP2D6 (0.46) | CYP2D6CYP2C19HRH3HRH1GNAI3 | |
| SCHEMBL22924119 | 0.88 | CYP2D6 (0.45) | CYP2D6CYP2C19HRH3HRH1GNAI3 | |
| SCHEMBL17623238 | 0.82 | CYP2D6 (0.38) | CYP2D6CYP2C19HRH3EHMT2SLC6A4 | |
| SCHEMBL21738353 | 0.82 | HRH3 (0.45) | CYP2D6CYP2C19HRH3HRH1GNAI3 | |
| SCHEMBL12712694 | 0.80 | GBA1 (0.40) | HRH3EHMT2 | |
| SCHEMBL13193525 | 0.80 | GBA1 (0.40) | HRH3EHMT2 | |
| SCHEMBL12712691 | 0.80 | GBA1 (0.40) | HRH3EHMT2 | |
| SCHEMBL26059858 | 0.80 | CYP2D6 (0.37) | CYP2D6CYP2C19HRH1 | |
| SCHEMBL6119492 | 0.79 | HRH3 (0.38) | CYP2D6CYP2C19HRH3HRH1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20210008023-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ARRAY BIOPHARMA, INC. | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008023-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | CYP2D6 3670/4885CYP2C19 3303/4885HRH3 364/4885 |
| US-20230142839-A1 | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | CYP2D6 3634/4885CYP2C19 3310/4885HRH3 386/4885 |
| US-20170252317-A1 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | ERBB4, ERBB2, ERBB3 | CYP2D6 3634/4885CYP2C19 3310/4885HRH3 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.